Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Prepaid Assets (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Prepaid Assets for 6 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Prepaid Assets rose 72.96% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, up 72.96% year-over-year, with the annual reading at $1.4 million for FY2025, 72.96% up from the prior year.
  • Prepaid Assets hit $1.4 million in Q4 2025 for Insight Molecular Diagnostics, up from $1.2 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $2.3 million in Q3 2021 to a low of $8000.0 in Q1 2021.
  • Historically, Prepaid Assets has averaged $1.1 million across 5 years, with a median of $1.1 million in 2022.
  • Biggest five-year swings in Prepaid Assets: plummeted 99.35% in 2021 and later surged 18837.5% in 2022.
  • Year by year, Prepaid Assets stood at $901000.0 in 2021, then rose by 8.44% to $977000.0 in 2022, then tumbled by 34.19% to $643000.0 in 2023, then rose by 27.68% to $821000.0 in 2024, then soared by 72.96% to $1.4 million in 2025.
  • Business Quant data shows Prepaid Assets for IMDX at $1.4 million in Q4 2025, $1.2 million in Q3 2025, and $1.3 million in Q2 2025.